Review on the clinical use of eribulin mesylate for the treatment of breast cancer

Volume: 17, Issue: 4, Pages: 589 - 600
Published: Feb 17, 2016
Abstract
Introduction: Breast cancer is the second leading cause of cancer death among women and the median survival of metastatic breast cancer (MBC) has remained, for many decades, at two to three years after diagnosis. Eribulin mesylate is a nontaxane inhibitor of microtubule dynamics and the only cytotoxic agent in the last decade to improve overall survival in heavily pretreated patients with MBC. Eribulin was approved for the treatment of MBC in...
Paper Details
Title
Review on the clinical use of eribulin mesylate for the treatment of breast cancer
Published Date
Feb 17, 2016
Volume
17
Issue
4
Pages
589 - 600
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.